Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis
Alejandro Balsa; Petra Díaz del Campo Fontecha; Lucía Silva Fernández; José Valencia Martín; Virginia Nistal Martínez; Fernando León Vázquez; M. Vanesa Hernández Hernández; Héctor Corominas; Rafael Cáliz Cáliz; José María Aguado García; Gloria Candelas Rodríguez; Nora Ibargoyen Roteta; Arturo Martí Carvajal; M. Nieves Plana Farras; Janet Puñal Riobóo; Hye Sang Park; Yolanda Triñanes Pego; Virginia Villaverde García;
Reumatol Clin. 2023;19:533-48
Practical aspects of biological throught levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis
José Rosas; María Martín-López; Teresa Otón; Alejandro Balsa; Jaime Calvo-Alén; Raimon Sanmartí; Jesús Tornero; Loreto Carmona;
Reumatol Clin. 2020;16P2:378-85
Fibromyalgia with elevated rheumatoid factor is associated with poor therapeutic response but not with progression to rheumatoid arthritis. Prospective cohort study
Freddy Liñán Ponce; Juan Leiva Goicochea; David Sevilla Rodríguez; Elmer Hidalgo Bravo; Ginna Obregón Atanacio; Inés Loyola Macalapú; Paola Jáuregui Rojas; Jackeline Yampufe Canani;
10.1016/j.reumae.2024.10.001